Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06351293
Other study ID # GLI.04.US.SL.034
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 21, 2024
Est. completion date February 28, 2025

Study information

Verified date March 2024
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, split-face, subject-blinded, comparative study. Subjects will receive initial treatment with Defyne on one of the NLFs and with RHA3 on the other based on the pre-determined randomization. 4 weeks after the initial treatment, subjects will receive optional touch-up on one side or both sides at the Investigator's discretion for optimal correction. Subjects to return to the site at Month 3, 6, and 12 for follow-ups.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 15
Est. completion date February 28, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 65 Years
Eligibility Inclusion Criteria: 1. Subjects 22 to 65 years of age. 2. Subjects with moderate-to-severe NLF based on the 5-point Wrinkle Severity Rating Scale (WSRS), and in the opinion of the investigator, is otherwise a good candidate for treatment with HA fillers. 3. Adult subjects of any gender, race, ethnicity, Fitzpatrick skin type, and sexual orientation. 4. Subjects with general good health. 5. Subjects who are willing to abstain from any other facial plastic surgical or cosmetic procedure(s) during the duration of the study. 6. For female subjects of childbearing potential, she must not be pregnant, breastfeeding or planning pregnancy during the course of the study. Subjects must be willing to take a urine pregnancy test (UPT) prior to all treatments. (Females of non-childbearing potential, e.g., post-menopausal (absence of menstrual bleeding for 1 year without any other medical reason), hysterectomy, or bilateral ovariectomy, are not required to have a UPT.) 7. Subjects who are able and willing to consent to the study informed consent form (ICF), Health Insurance Portability and Accountability Act of 1996 (HIPAA), and photography form prior to any study related procedures. 8. Subjects who agree to be photographed at each visit. 9. Subjects who agree to adhere to the procedures and requirements of the study, to report to the institute on the day(s) and at the time(s) scheduled for the assessments, and to complete all required visits. Exclusion Criteria: 1. Pregnant, breastfeeding, or planning pregnancy during the course of the study. 2. Current smokers or consumer of nicotine (e.g., cigarettes, e-cigarettes, vaping device with pre-filled pods, vapor tank or mod, chewing tobacco, nicotine replacement therapy). 3. Subjects with history of allergy or hypersensitivity to lidocaine and/or injectable HA. 4. Subjects with previous facial surgery, including aesthetic facial surgical therapy, liposuction, or tattoo in the treatment area. 5. Subjects with previous permanent or semi-permanent implant in proposed treatment area. 6. Subjects with previous biodegradable tissue augmentation therapy in the proposed treatment area within 12 months prior to the baseline visit. 7. Subjects with previous tissue revitalization treatment with neurotoxin in the facial area within 6 months prior to the baseline visit. 8. Subjects with history of other facial treatment/procedure at the study area (NLF) in the previous 6 months that would potentially interfere with study injections (e.g., oral surgery, laser or light therapy, chemical peeling, resurfacing, mesotherapy, dermabrasion). 9. Presence of any disease, lesions, or sign near or on the NLF region, e.g., 1. Inflammation, active, or chronic infection in or near the treatment area 2. Psoriasis, eczema, rosacea, atopic dermatitis, herpes zoster/herpes simplex, and acanthosis 3. Scars or deformities 4. Beard or facial hair 10. Subjects with history of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation (e.g., aspirin or other non-steroidal anti-inflammatory drugs), omega 3, or vitamin E within 14 days before treatment. Omega 3 and vitamin E are acceptable only as part of a standard multivitamin formulation. 11. Subjects with tendency to form keloids, hypertrophic scars, or any other healing disorder. 12. Planning on having surgeries and/or invasive medical procedures during the course of the study. 13. Treatment with chemotherapy, immunosuppressive agents, inhaled corticosteroids, immunomodulatory therapy (e.g., monoclonal antibodies or antiviral treatment for human immunodeficiency virus or hepatitis C) within 3 months prior to the baseline visit. 14. Subjects with history of cancer or previous radiation near or on the NLF region. 15. Human immunodeficiency virus positive or active hepatitis. 16. Subjects with any diseases, condition or presentation that may, in the opinion of the investigator, may put the subject at risk, may confound study results, or may interfere with participation in the study. 17. Study site personnel, close relatives of the study site personnel (e.g., parents, children, siblings, or spouse), or employees and close relatives of employees at the Sponsor company. 18. Subjects who have participated in any interventional study within 30 days of enrollment, or subjects planning to participate in any other interventional clinical research study while enrolled in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Defyne Treatment in Nasolabial Fold
Defyne will be injected into left or right nasolabial fold, per randomization.
RHA3 Treatment in Nasolabial Fold
RHA3 will be injected into left or right nasolabial fold, per randomization.

Locations

Country Name City State
United States The Aesthetic Clinique Santa Rosa Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Comparison of Nasolabial Fold Ultrasounds A single ultrasound assessment will be taken on each subject's left and right NLF, at neutral expression and at maximum smiling, in photo and video format. The placement of the ultrasound probe will be on the NLF, at the half-way point between nasal ala and oral commissure. Ultrasound assessments will be performed using an 18 MHz GE Venue Fit, a 20 MHz GE, and a 70 MHz Vevo MD ultrasonic transducer interfaced to a system. The probe will have a standard setting of gain, depth, and velocity scale to qualitatively assess placement/depth of filler, size of filler aggregates, and artery in NLF. Baseline, Week 4, Month 3, Month 6, Month 12
Secondary Volume Change Imaging Analysis Digital images of the subject's face will be taken of subject's face with a neutral expression and open-mouth maximum smiling expression. These images will be analyzed by VISIA-CRP software for nasolabial fold volume change compared to baseline. A decrease in scores indicates an improvement. Baseline, Week 4, Month 3, Month 6, Month 12
See also
  Status Clinical Trial Phase
Completed NCT05098912 - Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction N/A
Completed NCT05271136 - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum N/A
Completed NCT05096247 - Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device N/A
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT04128046 - The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation N/A
Active, not recruiting NCT04727099 - Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™ N/A
Active, not recruiting NCT06140628 - A 28-day Clinical Study on Facial Skin Rejuvenation N/A
Not yet recruiting NCT05524779 - BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement N/A
Completed NCT05514782 - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum N/A
Completed NCT06123572 - A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel N/A
Completed NCT04911374 - An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream N/A
Recruiting NCT04989361 - Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles. N/A
Recruiting NCT04540900 - A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions Phase 1
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Recruiting NCT06074276 - The Effects of Almond on Facial Skin Collagen and Wrinkles N/A
Completed NCT06366503 - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation N/A
Active, not recruiting NCT06219278 - A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles N/A
Active, not recruiting NCT06192550 - Functional Usability and Feasibility Testing of the Profound Matrix™ System N/A
Completed NCT04650620 - Study to Evaluate the Performance and Safety of the Medical Device Plenhyage® N/A
Completed NCT03729700 - The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome N/A